Opioid agonist treatment uptake within provincial correctional facilities in British Columbia, Canada

Original research
par
Kurz, M. et al

Date de publication

2021

Géographie

Canada

Langue de la ressource

English

Texte disponible en version intégrale

Non

Open Access / OK to Reproduce

Non

Évalué par des pairs

Yes

L’objectif

We aimed to estimate the impact of policy changes and the announcement of the opioid overdose-related public health emergency on the use of OAT for incarcerated individuals with opioid use disorder.

Constatations/points à retenir

Following an expansion of healthcare insurance coverage to include buprenorphine/naloxone, receipt of opioid agonist treatment (OAT) within correctional facilities in British Columbia, Canada increased, largely driven by an increase in buprenorphine/naloxone prescriptions among individuals without recent OAT experience.

La conception ou méthodologie de recherche

Interrupted time series analysis, n=9220. Events of interest included the expansion of buprenorphine/naloxone into provincial health care insurance coverage in October 2015 and the public health emergency declared in April 2016.

Mots clés

Policy/Regulatory
Legal system/law enforcement
Substitution/OAT